right to try

  • April 29, 2019  

    Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part Three

    With: Mark Shapiro, PhD

    A Q&A with Mark Shapiro, PhD,Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com. This is the final installment in a three-part series in which Dr. Shapiro has shared his thoughts on the question below. Read part 1 and part 2. Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater participation of such patients… Read more »

  • April 22, 2019  

    Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part Two

    With: Mark Shapiro, PhD

    A Q&A with Mark Shapiro, PhD,Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com. Last week, Dr. Shapiro shared his initial thoughts on the question below. Today, he discusses issues of cost and equitable access to care. Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater participation of such patients in clinical trials. In… Read more »

  • April 15, 2019  

    Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part One

    With: Mark Shapiro, PhD

    A Q&A with Mark Shapiro, PhD, Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater participation of such patients in clinical trials. In general, who pays the expenses of clinical trials? And, specifically, how are the costs for Right to Try and expanded-access approaches… Read more »

  • September 17, 2018  

    Options to Treat a Glioblastoma

    With: Al Musella, DPM

    Please see our updated version of this article from Oct 1, 2020. A Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY; email: musella@virtualtrials.com, phone: 888-295-4740 Q: You direct an established foundation that supports research and information about brain tumors. What would you do if you yourself were diagnosed with a glioblastoma multiforme (GBM)? A: Now… Read more »

  • April 2, 2018  

    Why Can’t Dying Patients Get the Drugs They Want? Bookmark

    Emma Shtivelman, PhD

    Excerpt:

    “At first glance, a bill passed by the House of Representatives this week seems like the kind of thing anyone could get behind.

    “Known as the “Right to Try” legislation, it would allow terminally ill patients access to experimental drugs without the approval of the Food and Drug Administration.

    “But the bill and a similar one passed last summer by the Senate do little to address the main barrier that patients face in getting unapproved treatments: permission from the drug companies themselves.”

    Go to full article published by The New York Times on Mar 23, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.